Awarding a European prize is equivalent to a validation of the Technology readiness level (TRL) of the project by an independent body (EASME).
2017 H2020 SME INSTRUMENT phase-2 Topic :SMEInst-03-2017. European commission
2015 H2020 SME INSTRUMENT phase-1 Topic : BIOTEC-5a2015. European commission
2015 17th i-Lab “Créadev” BPI France
2013 15th “émergence” OSEO/BPI
2013 – Innovation Days One of 15 finalists “Innovation Prize” Universal Biotech.
REGULAXIS is at the 2019 OARSI conference in Toronto from 2nd-5th of May !
OARSI World Congress on Osteoarthritis: Doctor Christelle Vêtu, CSO and Strategic Business Advisor will present the latest results during the poster session : “Chimeric Peptide combining both Growth Hormone and Somatostatin Sequences (REG-O3) improves function and prevents cartilage degradation in rat […]
Lors de la séance du 8 Avril du CLUB PME – ETI Claude CARELLI, Président et CEO de Regulaxis a présenté son entreprise et son « business model ». Les membres du Club l’ont « challengé » pour qu’il récolte le fruit de ce «brainstorming » collectif.
Engagée dans la R&D, Regulaxis développe des molécules […]
The offices of the Regulaxis Management Office are located at the feet of La Défense, the business district located in the Metropole du Grand Paris.
REG-O3, the innovative therapeutic treatment for Osteoarthritis will be tested in Liège !:
Artialis, specialist in the study of the musculoskeletal disorders and Regulaxis, an innovative French company in the treatment of osteoarthritis, announce today the signing of a 1.6 million euros contract for the preclinical and clinical development of a new molecule, Reg-O3, allowing […]
REGULAXIS, a leader in peptide research and development, will presents its most recent preclinical data of REG-O3, an innovative chimeric peptide for the treatment of osteoarthritis of knee at the 2018 Osteoarthritis Research Society International World Congress (OARSI), to be held April 26-29, 2018 in Liverpool, UK.
Regulaxis is proud to present the recent results on the effectiveness of REG-O3 in a model of traumatic knee osteoarthitis.
ACCEPTED POSTER :
“REG-O3, new chimeric peptides regulating IGF-1 pathway: significant therapeutic effect on ACLT rabbit model of osteoarthritis”
Raffaello PAOLINI, Rodrick MONTJEAN and Christelle VETU
Regulaxis is proud to announce to receive € 2.1m from EU Horizon 2020 SME instrument Phase 2 program for early gonarthrosis (OA) therapeutic drug regenerating cartilage !
Dr. Claude Carelli, President and CEO of REGULAXIS, presented to BIOCITECHDAY the innovative molecule under development for the therapeutic treatment of knee osteoarthritis.
17ème CONCOURS NATIONAL D’AIDE À LA CRÉATION D’ENTREPRISES INNOVANTES
Drs Christelle Vêtu and Claude Carelli are proud to announce that REGULAXIS has been awarded at the 17th National Contest for the Creation of Innovative Enterprises organized by the Ministry of Higher Education, Research and Innovation. The prize consists of a grant of € 200k.
Startup sélectionnée par Challenges dans les “100 startups ou investir 2014”
Awarding a European prize is equivalent to a validation of the Technology readiness level (TRL) of the project by an independent body (EASME).
2017 H2020 SME INSTRUMENT phase-2 Topic :SMEInst-03-2017. European commission
2015 H2020 SME INSTRUMENT phase-1 Topic : BIOTEC-5a2015. European commission
2015 17th i-Lab “Créadev” BPI France
2013 15th “émergence” OSEO/BPI
2013 – Innovation Days One of 15 finalists “Innovation Prize” Universal Biotech.